AMEDISYS INC (AMED)

US0234361089 - Common Stock

90.16  +0.16 (+0.18%)

After market: 90.16 0 (0%)

Fundamental Rating

5

AMED gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 113 industry peers in the Health Care Providers & Services industry. While AMED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMED has a correct valuation and a medium growth rate.



7

1. Profitability

1.1 Basic Checks

AMED had positive earnings in the past year.
AMED had a positive operating cash flow in the past year.
Of the past 5 years AMED 4 years were profitable.
In the past 5 years AMED always reported a positive cash flow from operatings.

1.2 Ratios

The Return On Assets of AMED (3.88%) is better than 76.99% of its industry peers.
AMED has a better Return On Equity (7.23%) than 72.57% of its industry peers.
AMED has a better Return On Invested Capital (9.98%) than 87.61% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMED is above the industry average of 8.10%.
Industry RankSector Rank
ROA 3.88%
ROE 7.23%
ROIC 9.98%
ROA(3y)5.6%
ROA(5y)7.71%
ROE(3y)10.94%
ROE(5y)15.06%
ROIC(3y)11.18%
ROIC(5y)12.42%

1.3 Margins

AMED has a Profit Margin of 3.57%. This is in the better half of the industry: AMED outperforms 76.11% of its industry peers.
Looking at the Operating Margin, with a value of 9.00%, AMED belongs to the top of the industry, outperforming 83.19% of the companies in the same industry.
In the last couple of years the Operating Margin of AMED has declined.
With a decent Gross Margin value of 43.67%, AMED is doing good in the industry, outperforming 72.57% of the companies in the same industry.
AMED's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 9%
PM (TTM) 3.57%
GM 43.67%
OM growth 3Y-1.84%
OM growth 5Y-1.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.18%
GM growth 5Y1.92%

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMED is still creating some value.
The number of shares outstanding for AMED has been increased compared to 1 year ago.
The number of shares outstanding for AMED has been increased compared to 5 years ago.
The debt/assets ratio for AMED has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 3.78 indicates that AMED is not in any danger for bankruptcy at the moment.
The Altman-Z score of AMED (3.78) is better than 81.42% of its industry peers.
AMED has a debt to FCF ratio of 1.88. This is a very positive value and a sign of high solvency as it would only need 1.88 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.88, AMED belongs to the best of the industry, outperforming 84.96% of the companies in the same industry.
AMED has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
AMED has a Debt to Equity ratio of 0.30. This is in the better half of the industry: AMED outperforms 62.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 1.88
Altman-Z 3.78
ROIC/WACC1.16
WACC8.63%

2.3 Liquidity

AMED has a Current Ratio of 1.19. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED has a worse Current ratio (1.19) than 64.60% of its industry peers.
AMED has a Quick Ratio of 1.19. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED's Quick ratio of 1.19 is in line compared to the rest of the industry. AMED outperforms 43.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 1.19

4

3. Growth

3.1 Past

AMED shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.88%.
AMED shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
AMED shows a small growth in Revenue. In the last year, the Revenue has grown by 4.19%.
Measured over the past years, AMED shows a small growth in Revenue. The Revenue has been growing by 6.11% on average per year.
EPS 1Y (TTM)-4.88%
EPS 3Y-11.17%
EPS 5Y3.28%
EPS Q2Q%2.04%
Revenue 1Y (TTM)4.19%
Revenue growth 3Y2.59%
Revenue growth 5Y6.11%
Sales Q2Q%5.65%

3.2 Future

Based on estimates for the next years, AMED will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.72% on average per year.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 7.17% on average per year.
EPS Next Y9.49%
EPS Next 2Y9.95%
EPS Next 3Y8.72%
EPS Next 5YN/A
Revenue Next Year5.27%
Revenue Next 2Y5.43%
Revenue Next 3Y7.17%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 21.02, AMED is valued on the expensive side.
AMED's Price/Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 71.68% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.96, AMED is valued a bit cheaper.
A Price/Forward Earnings ratio of 17.38 indicates a rather expensive valuation of AMED.
AMED's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 69.91% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AMED to the average of the S&P500 Index (23.82), we can say AMED is valued slightly cheaper.
Industry RankSector Rank
PE 21.02
Fwd PE 17.38

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than 66.37% of the companies in the same industry.
AMED's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMED is cheaper than 84.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.51
EV/EBITDA 13.17

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMED does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)2.21
PEG (5Y)6.4
EPS Next 2Y9.95%
EPS Next 3Y8.72%

0

5. Dividend

5.1 Amount

No dividends for AMED!.
Industry RankSector Rank
Dividend Yield N/A

AMEDISYS INC

NASDAQ:AMED (11/21/2024, 8:12:03 PM)

After market: 90.16 0 (0%)

90.16

+0.16 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.95B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 21.02
Fwd PE 17.38
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.21
PEG (5Y)6.4
Profitability
Industry RankSector Rank
ROA 3.88%
ROE 7.23%
ROCE
ROIC
ROICexc
ROICexgc
OM 9%
PM (TTM) 3.57%
GM 43.67%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.09
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.19
Quick Ratio 1.19
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-4.88%
EPS 3Y-11.17%
EPS 5Y
EPS Q2Q%
EPS Next Y9.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.19%
Revenue growth 3Y2.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y